Metabolic Dysfunction-Associated Steatotic Liver Disease and Emerging Oligonucleotide Therapies - PubMed
4 days ago
- #Liver Disease
- #Oligonucleotide Therapies
- #MASLD
- Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is a prevalent chronic liver condition with a global prevalence of ~30%.
- Current treatment options for MASLD are limited, necessitating novel therapeutic strategies.
- Oligonucleotide-based drugs, including ASO, siRNA, miRNA mimics/inhibitors, saRNA, and SSO, show promise for MASLD treatment.
- These therapeutics enable precise targeting of genes involved in MASLD pathogenesis.
- Advanced delivery systems like GalNAc conjugation enhance hepatocyte-specific targeting.
- Challenges in oligonucleotide drug development are discussed, along with future directions for the field.